| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | UPK3A |
| Uniprot No | O75631 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-207aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSHMVNLQPQLASVTFATNNPTLTTVALE KPLCMFDSKEALTGTHEVYLYVLVDSAISRNASVQDSTNTPLGSTFLQTE GGRTGPYKAVAFDLIPCSDLPSLDAIGDVSKASQILNAYLVRVGANGTCL WDPNFQGLCNPPLSAATEYRFKYVLVNMSTGLVEDQTLWSDPIRTNQLTP YSTIDTWPGRRSGG |
| 预测分子量 | 23 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于UPK3A重组蛋白的模拟参考文献(基于领域知识构造，供参考)：
---
1. **标题**：*Recombinant expression of uroplakin IIIa (UPK3A) in mammalian cells and its role in urothelial barrier formation*
**作者**：Smith J, Doe R, Chen L
**摘要**：研究利用哺乳动物HEK293细胞系统成功表达并纯化重组UPK3A蛋白，证实其与UPK2形成异源二聚体，并参与尿路上皮屏障功能的调控，为膀胱感染机制研究提供工具。
2. **标题**：*Bacterial expression and purification of functional UPK3A for antibody development*
**作者**：Wang X, Li M, Kumar S
**摘要**：通过大肠杆菌系统优化UPK3A重组蛋白的可溶性表达，利用镍柱亲和层析纯化，获得高纯度蛋白用于免疫小鼠，成功筛选出特异性识别天然UPK3A的单克隆抗体。
3. **标题**：*Crystal structure of recombinant UPK3A reveals key domains for urothelial plaque assembly*
**作者**：Brown K, Tanaka H, Zhang Y
**摘要**：采用昆虫杆状病毒系统表达重组UPK3A，通过冷冻电镜解析其三维结构，发现其跨膜结构域和胞外区对尿路上皮斑块组装的关键作用，为膀胱疾病治疗提供结构基础。
4. **标题**：*Recombinant UPK3A suppresses bladder cancer invasion by modulating EMT signaling pathways*
**作者**：Guo T, Liu F, Patel A
**摘要**：体外实验表明，重组UPK3A蛋白过表达可显著抑制膀胱癌细胞的迁移和侵袭，机制涉及上皮-间质转化(EMT)通路中E-cadherin的上调和Snail的下调。
---
**注**：以上文献为示例性内容，实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实发表的论文。
**Background of UPK3A Recombinant Protein**
Uroplakin 3A (UPK3A) is a key structural component of the urothelial plaques in the umbrella cells of the urinary bladder, forming part of the asymmetric unit membrane (AUM) critical for maintaining the permeability barrier and mechanical stability of the urothelium. It belongs to the uroplakin family, which includes UPK1A, UPK1B, UPK2. and UPK3A. These proteins assemble into heterotetrameric complexes (UPK1A/UPK3A or UPK1B/UPK3A) that polymerize into hexagonal arrays on the apical surface of urothelial cells, contributing to urine-blood barrier function.
Recombinant UPK3A protein is produced using biotechnological methods, often via heterologous expression systems like mammalian cells or *E. coli*, to ensure proper folding and post-translational modifications. Its recombinant form enables researchers to study UPK3A’s structural roles, interactions with other uroplakins, and involvement in urothelial physiology. Dysregulation of UPK3A has been linked to bladder pathologies, including urothelial carcinoma and interstitial cystitis, where altered expression may serve as a diagnostic marker or therapeutic target.
Additionally, recombinant UPK3A is used to generate antibodies for immunohistochemistry, Western blotting, and diagnostic assays. It also aids in investigating bacterial adhesion mechanisms, as uroplakins are receptors for uropathogenic *E. coli*. The protein’s role in maintaining urothelial integrity underscores its relevance in tissue engineering and regenerative medicine. Ongoing research explores its potential in bladder repair strategies and as a biomarker for urinary tract diseases.
In summary, UPK3A recombinant protein is a vital tool for advancing understanding of urothelial biology, disease mechanisms, and therapeutic development.
×
